Format

Send to

Choose Destination
J Neuroinflammation. 2018 Oct 15;15(1):288. doi: 10.1186/s12974-018-1326-y.

Leukemia inhibitory factor modulates the peripheral immune response in a rat model of emergent large vessel occlusion.

Author information

1
Department of Neurology, University of Kentucky, 741 S. Limestone BBSRB B457, Lexington, KY, 40536-0905, USA.
2
Department of Neuroscience, University of Kentucky, 800 Rose St. Lexington, Lexington, KY, 40536, USA.
3
Department of Molecular Pharmacology and Physiology, University of South Florida, 12901 Bruce B. Downs Blvd MDC 8, Tampa, FL, 33612, USA.
4
Department of Molecular Medicine, University of South Florida, 12901 Bruce B. Downs Blvd MDC 7, Tampa, FL, 33612, USA.
5
Department of Physiology, University of Kentucky, 800 Rose St. MS508, Lexington, KY, 40536, USA.
6
Spinal Cord and Brain Injury Repair Center, University of Kentucky, 741 S. Limestone BBSRB B463, Lexington, KY, 40536, USA.
7
Department of Neurology, University of Kentucky, 741 S. Limestone BBSRB B457, Lexington, KY, 40536-0905, USA. keith.pennypacker@uky.edu.
8
Department of Neuroscience, University of Kentucky, 800 Rose St. Lexington, Lexington, KY, 40536, USA. keith.pennypacker@uky.edu.

Abstract

BACKGROUND:

The migration of peripheral immune cells and splenocytes to the ischemic brain is one of the major causes of delayed neuroinflammation after permanent large vessel stroke. Other groups have demonstrated that leukemia inhibitory factor (LIF), a cytokine that promotes neural cell survival through upregulation of antioxidant enzymes, promotes an anti-inflammatory phenotype in several types of immune cells. The goal of this study was to determine whether LIF treatment modulates the peripheral immune response after stroke.

METHODS:

Young male (3 month) Sprague-Dawley rats underwent sham surgery or permanent middle cerebral artery occlusion (MCAO). Animals were administered LIF (125 μg/kg) or PBS at 6, 24, and 48 h prior to euthanization at 72 h. Bone marrow-derived macrophages were treated with LIF (20 ng/ml) or PBS after stimulation with interferon gamma + LPS. Western blot was used to measure protein levels of CD11b, IL-12, interferon inducible protein-10, CD3, and the LIF receptor in spleen and brain tissue. ELISA was used to measure IL-10, IL-12, and interferon gamma. Isolectin was used to label activated immune cells in brain tissue sections. Statistical analysis was performed using one-way ANOVA and Student's t test. A Kruskal-Wallis test followed by Bonferroni-corrected Mann-Whitney tests was performed if data did not pass the D'Agostino-Pearson normality test.

RESULTS:

LIF-treated rats showed significantly lower levels of the LIF receptor and interferon gamma in the spleen and CD11b levels in the brain compared to their PBS-treated counterparts. Fluorescence from isolectin-binding immune cells was more prominent in the ipsilateral cortex and striatum after PBS treatment compared to LIF treatment. MCAO + LIF significantly decreased splenic levels of CD11b and CD3 compared to sham surgery. MCAO + PBS treatment significantly elevated splenic levels of interferon inducible protein-10 at 72 h after MCAO, while LIF treatment after MCAO returned interferon inducible protein 10 to sham levels. LIF administration with interferon gamma + LPS significantly reduced the IL-12/IL-10 production ratio compared to macrophages treated with interferon gamma + LPS alone.

CONCLUSIONS:

These data demonstrate that LIF promotes anti-inflammatory signaling through alterations of the IL-12/interferon gamma/interferon inducible protein 10 pathway.

KEYWORDS:

Cytokines; Inflammation; Ischemia; Macrophages; Stroke

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center